Unicycive Therapeutics (UNCY) Stock: Buy, Sell, or Hold?
UNCY - Unicycive Therapeutics, Inc. Common Stock
$4.22
-0.33 (-7.25%)
▼
5d:
-10.12%
30d:
-18.69%
90d:
-21.27%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When UNCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: UNCY is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: UNCY is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.31
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$2.05
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UNCY is currently trading at $4.22, which is considered oversold relative to its 30-day fair value range of $4.67 to $5.30. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.5) compared to its historical average (1.4). At these levels, the market is pricing in 21.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UNCY is in a strong downtrend. Immediate support is located at $4.09, while resistance sits at $4.97. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: UNCY scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.40 (+573.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UNCY is in a strong downtrend. Immediate support is located at $4.09, while resistance sits at $4.97. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: UNCY scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.40 (+573.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.67 -
$5.30
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
51.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.3%)
- BULLISH: Trading 573.0% below Wall St target ($28.40)
- NEUTRAL: Trading at premium valuation - market expects 21.5% growth which is achievable
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.67 -
$5.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.09
Resistance Level
$4.97
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.50
Wall Street Target
$28.40
(+573.0%)
Valuation Premium vs History
+21.5% premium
PE vs Historical
2.5 vs 1.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+21.5%
(market-implied from PE analysis)
1-Year Target
$5.13
(+22%)
2-Year Target
$6.23
(+48%)
3-Year Target
$7.57
(+79%)
3-Yr Target (if PE normalizes)
(PE: 3→1)
PE COMPRESSION
$4.23
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 03, 2026 12:10 PM ET
Data refreshes hourly during market hours. Next update: 1:10 PM
Data refreshes hourly during market hours. Next update: 1:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UNCY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
